Latest news with #antibodies
Associated Press
12-08-2025
- Business
- Associated Press
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
Schlieren/Zurich, Switzerland, August 12, 2025 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has raised a total of CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a capital increase and a convertible loan of CHF 15 million, respectively. The funds are provided by Mabylon's existing private investors, with the major investment coming from former management and board members of Roche. The funding will allow Mabylon to advance its lead program MY006, a tri-specific antibody neutralizing peanut allergens, to completion of a Phase Ia/b trial in 2027 with the goal to generate robust safety and preliminary efficacy data. In addition, the funding will enable Mabylon to further develop its discovery and pre-clinical programs. These include MY010, a multi-specific and cross-reactive antibody targeting the birch Bet v 1 allergen, as well as all the major birch-related tree, fruit and nuts allergens. The funding will also support development of MY011, an antibody product for treating grass pollen allergies. At the shareholders' assembly, Dr. Thomas Hecht was elected as a new member of Mabylon's Board of Directors. He succeeds Prof. Adriano Aguzzi, whose term ended in June 2025. 'MY006 is a multi-specific anti-allergen antibody for the prophylactic treatment of peanut allergy, an indication with a high unmet medical need. The funds will enable Mabylon to reach clinical proof-of-concept and further advance its early-stage pipeline,' said Gottlieb Keller, Chairman of Mabylon's Board of Directors. 'I would like to thank Prof. Adriano Aguzzi for his contributions to the board and welcome Thomas Hecht as a new board member.' 'We are very pleased to have closed a CHF 30 million financing agreement in such a challenging global funding environment. This is a strong validation of our approach using human-derived, multi-specific antibodies for the treatment of allergies,' said Alcide Barberis, PhD, CEO of Mabylon. 'We also warmly welcome Dr. Thomas Hecht to our Board of Directors. He brings outstanding industry expertise and will help us advance and commercialize our pipeline of best-in-class allergen-neutralizing antibodies.' ### About Mabylon AG Mabylon is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. Human-derived antibodies have superior therapeutic potential compared to antibodies derived from conventional sources, such as humanized animal models or artificial libraries. In the case of allergy, for instance, Mabylon's antibodies derived from allergic patients target disease-relevant epitopes, expanding the knowledge of novel allergenic epitopes and their role in disease progression. For more information, please visit Contact Alcide Barberis, CEO Mabylon AG Wagistrasse 14 8952 Schlieren (Zurich Area), Switzerland Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 /Tel. +49 30 23 63 27 68
Telegraph
08-08-2025
- Health
- Telegraph
Antibodies raise vaccine hopes for a bug that kills 500,000 a year
The discovery of antibodies thought to protect children against a common bacterial infection could bring a vaccine against a bug that kills 500,000 each year. Scientists at the University of Sheffield and the Medical Research Council (MRC) have for the first time identified specific antibodies that protect against Strep A. The common bacterium is mainly known for causing sore throats and flu-like symptoms, but in more invasive cases it can be deadly. The bug kills hundreds of thousands of people each year in poor and middle-income countries, and a UK outbreak in 2022/23 caused more than 400 deaths. Researchers tracked children in The Gambia, and discovered that while maternal protection faded, young children quickly mounted immune responses to parts of the bug. Until now, a limited understanding of the body's natural defences against the bug, which is also called Streptococcus pyogenes, has hindered any vaccine development. The findings of the peer-reviewed study, which are published in the Nature Medicine journal, are a potential breakthrough to develop a new jab. Dr Alex Keeley, a Wellcome fellow in global health at the MRC's Gambia unit and Sheffield's Florey Institute of Infection, led the research. He said: 'Our findings represent a significant step towards a safe and effective vaccine that could save around half a million lives here in the UK and around the world.' 'Now, for the first time in humans, we've been able to observe how antibodies that would be made following vaccination may be preventing infections and show how these antibodies may be working against Strep A.' Fatouamta Camara, who worked on the research, said Strep A in the Gambia 'carries a devastating burden on children and adults in their prime years'. She said: 'Beyond causing illness, its impact ripples through families and communities, perpetuating cycles of poverty and reducing quality of life. 'A vaccine offers hope as a powerful tool to prevent these infections, protect our communities, and improve health outcomes, enabling children and young people to thrive.'
Yahoo
02-07-2025
- Business
- Yahoo
Boster Bio Launches Free Antibody Validation Service to Transform Research Reproducibility
Pleasanton, July 02, 2025 (GLOBE NEWSWIRE) -- In a bold move that could reshape the future of biomedical research, Boster Bio is launching a —giving scientists the power to test antibodies under their exact experimental conditions before purchase. It's a first-of-its-kind, no-cost service that tackles one of science's most frustrating pain points: unreliable antibodies. "For too long, researchers have had to gamble on antibodies that may or may not work," said CJ Xia, Founder and VP of Boster Bio. "We believe that's unacceptable. Our free validation service gives you proof before you pay—so your research runs smoother, faster, and with far fewer surprises." Antibodies are the backbone of modern life sciences. Yet according to studies, over 50% of research antibodies are poorly validated, leading to inconsistent results, failed experiments, and wasted budgets. Boster Bio's solution: A fast, AI-assisted validation pipeline that tests antibodies for specificity and performance using over 500 in-house tissue and lysate types across applications like Western blot (WB), IHC, IF, ELISA, FC, and IP—all tailored to the researcher's exact assay needs. How It Works: Submit in 2 Minutes: Fill out a quick online form or reply by email with a biomarker list, sample types, and applications. They Test: Their team validates the requested antibodies in-house—no samples or reagents needed from one's lab. Fast Turnaround: Receive a full validation report, including protocols and results, in 4–10 days. With time and funding tighter than ever, researchers deserve tools that help them focus on publishing, not troubleshooting. Boster Bio's Free Validation Service eliminates trial-and-error by front-loading the proof. Labs can even submit up to 100 biomarkers at once, making it ideal for screening large panels. "We're not just providing reagents," Xia adds. "We're changing expectations. In five years, people will look back and wonder how they ever ordered antibodies without seeing validation data first. This is the new normal." Interested researchers can submit their validation requests via: In addition to its free validation service, Boster Bio offers —a fast, tailored solution for researchers who need highly specific, high-affinity antibodies built from the ground up. Leveraging decades of expertise in immunogen design and hybridoma technology, Boster Bio guides researchers through every step: from antigen design and immunization to hybridoma screening and large-scale production. "We design each antigen strategically—accounting for homology, post-translational modifications, epitope localization, and protein structure—so you get antibodies that hit exactly where you need them," said CJ Xia. With turnaround times as short as eight weeks, the process balances speed with scientific rigor. Each batch undergoes strict quality controls, including titer testing and cross-reactivity screening, ensuring performance you can trust in assays like WB, IHC, IF, ICC, ELISA, and Flow Cytometry. Researchers can choose from a growing inventory of over 8,000 antibodies and 500 sample types (including human, mouse, rat, monkey, and zebrafish), or start completely from scratch. By combining free validation with custom development, Boster Bio now delivers a true end-to-end antibody solution—positioning itself as a single, reliable partner for labs aiming to publish faster, waste less, and innovate more. About the Company: Boster Bio is a leading manufacturer of antibodies and ELISA kits critical to advancing life science research. Specializing in custom monoclonal antibody production services and offering free antibody validation, the company supports researchers with high-quality reagents and exceptional service. Based in Pleasanton, CA, Boster Bio continues to innovate in antibody development and immunoassay solutions. ### For more information about Boster Biological Technology, contact the company here:Boster Biological TechnologyCJ Xia(888) 466-3604sales@ Valley Ave, Pleasanton, CA 94566, USA CONTACT: CJ XiaSign in to access your portfolio
Yahoo
20-06-2025
- Science
- Yahoo
New Tech Adapted From Solar Cells Could Make Drug Development Faster, Cheaper
From mass spectrometry to thermogravimetric analysis, one of the most expensive and time-consuming tasks in modern chemistry is figuring out what you've got. It turns out that just isolating a sample, or even synthesizing one, is often only half the battle. The other half is proving the identity and concentration of whatever that sample contains—and that's the target of a new innovation from a startup called Advanced Silicon Group. The tech takes diverse solutions of proteins, even complex solutions with multiple proteins at once, and passes them over a series of silicon nanowires that can bind to certain proteins. They claim that it can identify and quantify an array of different proteins in less than 15 minutes, requires less of the sample solution to work, and provides more accurate results. Let's talk about how it works. Both this method of quantifying proteins and traditional ones share the basic type of approach: antibodies. The legacy test, and still the mainstay in modern laboratories, is called ELISA, or Enzyme-linked ImmunoSuppressant Assay. It works by washing liquid mixtures of proteins over a plate coated with antibodies that bind to a specific protein—yet again, using evolved biological molecules to do jobs we still struggle to do, directly. If you've ever taken a biochemistry lab course, you've likely encountered ELISA test. Credit: GETTY IMAGES If present, the protein of interest will bind to the specifically chosen antibody and become stuck to the plate, which is then washed again with another antibody that also binds to this same protein. This second antibody attachment comes with a marker, though, which can be activated to become visible. So, the more color, the more of the protein of interest. The problem is that ELISA requires a fair amount of training and time, and it also requires a fair volume of the solution being tested. The color-based analysis is also only a blunt way of quantifying the signal, meaning that its sensitivity often leaves something to be desired. It's an old style of chemical test, both literally and figuratively messy and requiring expertise to scry the results. This innovation offers the same path forward as solutions to similar situations in the past, such as DNA sequencing and electrochemistry. This new tech also works through binding of antibodies, but this time they are bound to silicon nanowires that easily conduct electricity. It's actually an adaptation of a design for a solar photovoltaic cell, and still involves exposure to light; scientists wash their sample solution over the antibody-bound nanowires, and again end up with it bound to antibodies. The new tech works based on how proteins bound to a nanowire disrupt that nanowire's regular reaction to light. Credit: Advanced Silicon Group This time, though, the next step is to hit the experiment with light. That's because the protein-bound nanowires will create a current from this light more readily than the non-protein-bound nanowires. This allows researchers to use the strength of the current created to quantify the protein—and because the antibody used was chosen to bind to only the protein of interest, we know that the concentration is of interest. This level of current allows much more specific results, and ones that can be quantified by a computer, rather than by a chemist. Automation might be controversial in some industries—but most people are in favor of any innovation that leads patients to receive more, better drugs. 'We're making it 15 times faster and 15 times lower cost to test for proteins,' the researchers told MIT News. 'That's on the drug development side. This could also make the manufacturing of drugs significantly faster and more cost-effective. It could revolutionize how we create drugs in this country and around the world.' The new approach is quicker and much less messy, requiring less training in laboratory processes. Credit: Advanced Silicon Group Faster, cheaper, better protein sensing would assist scientists in searching for specific proteins in potential sources for new therapies, and in patient fluid samples. On the other hand, it could also help drug manufacturing move much more quickly, and more efficiently hone in on the best methods that create the purest products. The technology could also be used for direct diagnosis of certain ailments that have protein-based markers for identification; the researchers themselves suggest lung cancer as a potential first target. Check out all ExtremeTech's coverage of drug development.
Associated Press
16-06-2025
- Business
- Associated Press
AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets
Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ACCESS Newswire / June 16, 2025 / AbTherx, a biotechnology company with innovative technologies that enable therapeutic antibody discovery against challenging targets, today announced a research collaboration with GPCR Therapeutics, a clinical-stage biopharmaceutical company, to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets. AbTherx's antibody discovery platform is built on two decades of experience and utilizes the immune system's evolutionary intelligence to identify diverse and developable human antibodies. This collaboration leverages AbTherx's innovative, patent-pending Atlas Long CDR3 Mouse to create antibodies with long CDR3 regions, providing the unique opportunity to access buried epitopes within GPCRs, ion channels, and other difficult targets. These fully human antibodies minimize developability and immunogenicity risk by leveraging a rare, naturally occurring phenomenon in humans. GPCR Therapeutics is developing drugs targeting GPCRs to treat cancer, fibrosis, and obesity. Its stem cell mobilization program is now undergoing a phase 2 clinical trial in the United States of America. The company has also established capabilities for antigen development, antibody screening, and profiling for the discovery of antibodies targeting GPCRs, which are historically known to be challenging targets for antibody discovery. 'We are excited to strategically partner with GPCR Therapeutics to co-create a potentially life-saving therapeutic, leveraging the full power of the AbTherx team, combining a potentially best-in-class antibody discovery platform with a highly successful team of drug hunters,' said Justin Mika, CEO of AbTherx. 'This collaboration is a first for our proprietary Atlas Long CDR3 Mouse. We are keen to explore the full potential of this technology to discover and develop transformative, new antibody therapies for challenging targets.' 'We are thrilled to collaborate with one of the world's most experienced antibody discovery teams,' said Dong Seung Seen, CEO of GPCR Therapeutics. 'Our partnership with AbTherx marks a significant milestone for GPCR Therapeutics, strategically enhancing our ability to generate therapeutic antibodies against our priority targets. By combining our respective strengths, we aim to explore the largely uncharted territory of GPCR-targeting antibodies, ultimately striving to bring multiple first-in-class therapies to patients. The potential to expand our focus to additional targets in oncology, fibrosis, and obesity, further underscores the strategic value of this collaboration.' AbTherx has a range of partnering strategies from technology licensing to strategic collaborations. The Long CDR3 technology has the potential to deliver high-impact therapeutics for some of the most challenging targets. It is available for strategic research collaborations and co-development partnerships aimed at advancing innovative therapeutics. This AbTherx and GPCR Therapeutics partnership is expected to yield a pre-clinical asset governed by a 50/50 ownership structure, drawing on the complementary strengths and resources of both parties to develop a novel modality targeting GPCRs, the largest and most diverse family of drug targets. About AbTherx AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit About GPCR Therapeutics GPCR Therapeutics, Inc. is a clinical-stage biopharmaceutical company taking an innovative approach to developing therapeutics based on its proprietary GPCR science. The company is currently conducting a Phase 2 clinical trial in the U.S. to evaluate the efficacy of GPC-100 in combination with propranolol in patients with multiple myeloma, in collaboration with Exicure. In addition to its lead program, GPCR Therapeutics is advancing multiple partnerships with pharmaceutical and biotech companies to develop therapies targeting cancer, fibrosis, obesity, and rare diseases. The company is headquartered in Seoul, South Korea. For more information, please visit AbTherx Media Contact Stacey Borders [email protected] SOURCE: AbTherx, Inc press release
